ArticleScientific reports2026
Combined mesenchymal stem cells and metformin therapy modulates key macromolecular pathways in pulmonary fibrosis based on evidence from untargeted metabolomics.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease with limited therapeutic options, highlighting the need for novel interventions. Mesenchymal stem cells (MSCs) possess immunomodulatory and regenerative capacities, while metformin, a widely used antidiabetic agent, has recently shown anti-fibrotic potential through metabolic reprogramming. Metabolomic profiling offers a comprehensive approach to elucidate disease-associated biochemical alterations and therapeutic mechanisms. In this pilot study, bleomycin-induced pulmonary fibrosis in rats was treated with MSCs, metformin, or their combination. Untargeted LC-MS-based metabolomics of plasma and lung tissue, alongside histopathological evaluation, revealed that combination therapy most effectively corrected metabolic disruptions and attenuated fibrotic remodeling. Histology confirmed marked reductions in alveolar wall thickening, collagen deposition, and fibroblastic foci in the combination group compared to monotherapies. Metabolite changes in lung tissue included sphingosine (lipid metabolism), 5-hydroxyindoleacetic acid (serotonin turnover), cyclic GMP (nitric oxide signaling), and 4-guanidinobutanoic acid (arginine/creatine metabolism). Plasma regulation involved corticosterone (steroid biosynthesis), PC (18:2/18:2) (phospholipid remodeling), methionine (methylation balance), galactose 1-phosphate (carbohydrate metabolism), and niacinamide (NAD⁺ biosynthesis). These findings provide preliminary evidence that combined MSCs–metformin therapy synergistically ameliorates fibrosis and metabolic dysregulation, while identifying metabolites that may serve as potential biomarkers for disease progression and therapeutic response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.